Figures computed from official regulatory filings — .
Analysttarget 116.67 USD (+24%) · consensus 4.57/5 · 6 buy · 1 hold · 0 sell
Ownershipinsiders 5.16% · institutions 105.57% · short 26.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Kodiak Sciences Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
310 buys152 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LPtrack record | Buy | $84.9K | conv 22 |
| BAKER BROS. ADVISORS LPtrack record | Buy | $97K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $17.7M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $102.1K | conv 21 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $140.5K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $10.4M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $121.6K | conv 21 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $7.2K | conv 21 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $459.1K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $544.2K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $1.4M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $3.2K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $27.4K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $83K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $3.3M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $281K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $1.3M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $42.4K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $1.2M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $20.2M | conv 23 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $6.6M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $1.1M | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $176.7K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $516.8K | conv 22 | SEC |
| BAKER BROS. ADVISORS LPtrack record | Buy | $5.7M | conv 22 | SEC |